patient management

Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study

Study Overview The study investigates the efficacy of three therapeutic agents—ripertamab, rituximab, and efgartigimod—in treating chronic inflammatory demyelinating polyneuropathy (CIDP),

Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study Read Post »

Scroll to Top